Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
Clinical trial NCT03004248 · COMPLETED
Trial details
- NCT number
- NCT03004248
- Sponsor
- Revance Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-09
- Primary completion
- 2018-10-17
- Enrollment
- 2691
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.